Table 2.
The 3 selected isolates SHE, S11P and S5, response to the produced nano particles and drug of choice against ATCC bacterial strains according to zone inhibition in millimeter.
| Tested pathogenic strain | Tested antimicrobial agents | |||
|---|---|---|---|---|
| CRO | DA | CN | SN | |
| Isolate SHE AgNPs | ||||
| S. aureus | 20 | 25 | NT | 16 |
| S. epidermidis | 30 | 30 | NT | 17 |
| P. aeruginosa | NT | NT | 19 | 14 |
| E. coli | 29 | NZI | NT | 11 |
| K. pneumoniae | 29 | NZI | NT | 19 |
|
| ||||
| Isolate S11P AgNPs | ||||
| S. aureus | 22 | 23 | NT | 12 |
| S. epidermidis | 3.2 | 3 | NT | 1.3 |
| P. aeruginosa | NT | NT | 19 | 15 |
| E. coli | 28 | NZI | NT | 10 |
| K. pneumoniae | 24 | NZI | NT | 14 |
|
| ||||
| Isolate S5 AgNPs | ||||
| S. aureus | 20 | 25 | NT | 12 |
| S. epidermidis | 32 | 3 | NT | 11 |
| P. aeruginosa | NT | NT | 19 | 13 |
| E. coli | 29 | NZI | NT | 10 |
| K. pneumoniae | 29 | NZI | NT | 15 |
NT: not tested; NZI: no zone of inhibition was observed; CRO: ceftriaxone; DA: clindamycin; CN: gentamicin; SN: silver nanoparticles.